{
    "id": "621938e1-2248-4ce5-948b-435c4bf56cd2",
    "indications": {
        "text": "risperidone atypical antipsychotic indicated : \u2022 treatment schizophrenia ( 1.1 ) \u2022 monotherapy adjunctive therapy lithium valproate , treatment acute manic mixed episodes associated bipolar disorder ( 1.2 ) \u2022 treatment irritability associated autistic disorder ( 1.3 )",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "bipolar disorder (DOID:3312)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3312"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "table 1 recommended daily indication initial dose titration ( increments ) target dose effective dose range schizophrenia : adults ( 2.1 ) 2 mg 1 2 mg 4 8 mg 4 16 mg schizophrenia : adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 3 mg 1 6 mg bipolar mania : adults ( 2.2 ) 2 3 mg 1 mg 1 6 mg 1 6 mg bipolar mania : children adolescents ( 2.2 ) 0.5 mg 0.5 1 mg 1 2.5 mg 1 6 mg irritability autistic disorder ( 2.3 ) 0.25 mg increase 0.5 mg day 4 : ( body weight less 20 kg ) 0.5 mg increase 1 mg day 4 : ( body weight greater equal 20 kg ) day 4 , intervals > 2 weeks : 0.25 mg ( body weight less 20 kg ) 0.5 mg ( body weight greater equal 20 kg ) 0.5 mg : ( body weight less 20 kg ) 1 mg : ( body weight greater equal 20 kg ) 0.5 3 mg severe renal hepatic impairment adults : lower starting dose 0.5 mg twice daily . may increase dosages 1.5 mg twice daily intervals one week longer .",
        "doid_entities": [
            {
                "text": "schizophrenia (DOID:5419)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5419"
            },
            {
                "text": "autistic disorder (DOID:12849)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_12849"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "severe renal hepatic",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_42738"
            }
        ]
    },
    "warningsAndPrecautions": "risperidone tablets usp , 0.5 mg red-brown colored , round , biconvex film-coated tablets debossed `` z `` one side `` 6 `` side supplied follows : overbagged 10 film-coated tablets per bag , ndc 55154-0180-0 risperidone tablets usp , 1 mg white off-white , round , biconvex film-coated tablets debossed `` zc 75 `` one side plain side supplied follows : overbagged 10 film-coated tablets per bag , ndc 55154-2634-0",
    "adverseReactions": "risperidone contraindicated patients known hypersensitivity either risperidone paliperidone , excipients risperidone formulation . hypersensitivity , including anaphylactic angioedema , reported patients treated risperidone patients treated paliperidone . paliperidone metabolite risperidone .",
    "ingredients": [
        {
            "name": "RISPERIDONE",
            "code": "L6UH7ZF8HC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_28017"
        },
        {
            "name": "HYPROMELLOSE, UNSPECIFIED",
            "code": "3NXW29V3WO",
            "drugbank_id": "https://go.drugbank.com/drugs/DB11075"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16189"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        }
    ],
    "organization": "Cardinal Health 107, LLC",
    "name": "risperidone",
    "effectiveTime": "20250519",
    "indications_original": "Risperidone is an atypical antipsychotic indicated for: \u2022 Treatment      of schizophrenia ( 1.1 ) \u2022 As      monotherapy or adjunctive therapy with lithium or valproate, for the      treatment of acute manic or mixed episodes associated with Bipolar I      Disorder ( 1.2 ) \u2022 Treatment      of irritability associated with autistic disorder ( 1.3 )",
    "contraindications_original": "Table 1 Recommended Daily Dosage by Indication \n                     \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                           \n                              \n                                  Initial Dose \n                                 \n                              \n                           \n                           \n                              \n                                  Titration \n                                 \n                                  (Increments) \n                                 \n                              \n                           \n                           \n                              \n                                  Target Dose \n                                 \n                              \n                           \n                           \n                              \n                                  Effective Dose \n                                 \n                                  Range \n                                 \n                              \n                           \n                        \n                        \n                           \n                               Schizophrenia: adults (2.1) \n                              \n                           \n                           \n                               2 mg\n                              \n                           \n                           \n                               1 to 2 mg\n                              \n                           \n                           \n                               4 to 8 mg\n                              \n                           \n                           \n                               4 to 16 mg\n                              \n                           \n                        \n                        \n                           \n                               Schizophrenia:  adolescents  (2.2) \n                              \n                           \n                           \n                               0.5 mg\n                              \n                           \n                           \n                               0.5 to 1 mg\n                              \n                           \n                           \n                               3 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Bipolar mania: adults (2.2) \n                              \n                           \n                           \n                               2 to 3 mg\n                              \n                           \n                           \n                               1 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Bipolar mania:  children and  adolescents  (2.2) \n                              \n                           \n                           \n                               0.5 mg\n                              \n                           \n                           \n                               0.5 to 1 mg\n                              \n                           \n                           \n                               1 to 2.5 mg\n                              \n                           \n                           \n                               1 to 6 mg\n                              \n                           \n                        \n                        \n                           \n                               Irritability in autistic  disorder (2.3) \n                              \n                           \n                           \n                               0.25 mg Can increase to 0.5 mg by Day 4: (body weight less than 20 kg) 0.5 mg Can increase to 1 mg by Day 4: (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               After Day 4, at intervals of > 2 weeks: 0.25 mg (body weight less than 20 kg) 0.5 mg (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               0.5 mg: (body weight less than 20 kg) 1 mg: (body weight greater than or equal to 20 kg)\n                              \n                           \n                           \n                               0.5 to  3 mg\n                              \n                           \n                        \n                     \n                  \n                  Severe Renal and Hepatic Impairment in Adults: use a lower starting dose of 0.5 mg twice daily.\n                  May increase to dosages above 1.5 mg twice daily at intervals of one week or longer.",
    "warningsAndPrecautions_original": "Risperidone Tablets USP, 0.5 mg are red-brown colored, round, biconvex film-coated tablets debossed with \"Z\" on one side and \"6\" on other side and are supplied as follows:\n                        Overbagged with 10 film-coated tablets per bag,\u00a0NDC 55154-0180-0\n                        Risperidone Tablets USP, 1 mg are white to off-white, round, biconvex film-coated tablets debossed with \"ZC 75\" on one side and plain on other side and are supplied as follows:\n                        Overbagged with 10 film-coated tablets per bag,\u00a0NDC 55154-2634-0",
    "adverseReactions_original": "Risperidone is contraindicated in patients with a known hypersensitivity to either risperidone or paliperidone, or to any of the excipients in the risperidone\u00a0formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of risperidone.",
    "drug": [
        {
            "name": "risperidone",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8871"
        }
    ]
}